Fundraising FoxNewton Biocapital
Venture capitalBrussels · Seed–Series A · 16 people tracked
Find your way into Newton Biocapital
Sign up to see every warm intro you have to Newton Biocapital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Newton Biocapital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Newton Biocapital invests in life sciences innovation across Europe and Japan, leveraging strong ties to both regions' ecosystems to unlock cross-border opportunities and optimal exits through connections with local and international investors and pharma. The fund targets promising solutions for chronic health conditions with an aim to reduce patient and societal burdens. Drawing on the team's scientific and medical expertise plus a network of experts, the firm identifies opportunities across a range of technologies and disease areas, and participates actively as board members, supporting portfolio companies with their preclinical and clinical program selection to create value for patients, society, local ecosystems, and investors.
Source: firm website, verified Aug 3, 2026.
Team · 16 people
from the firm's website & curated & public directories
What they invest in
from 16 of 18 portfolio companiesBiotech ×14Medical Devices ×12Healthtech ×11Deep Tech ×6Digital Health ×4AI & Machine Learning ×3Longevity ×1
HQs:Belgium×5Japan×4European Union×1France×1
Who they back
founder profiles across 8 portfolio companiesFounding team size:solo founder×62 founders×13 founders×1
Investments · 18 tracked
founders shown can be your intro pathBy year:2023 · 12022 · 12021 · 12019 · 12018 · 15 dated
AbolerIS Pharma develops therapeutic approaches that regulate the immune system by inducing immune tolerance while preserving useful immune responses, targeting inflammatory, autoimmune, and degenerative diseases.
BiotechHealthtech
Ignacio Anegon(Co-founder, Senior Consultant & SAB Member)inCarole Guillonneau(Co-founder & Head of Research)inFrançois-Xavier Hubert(Co-founder, Past President & Board Member)
Co-investorsCriteria Bio VenturesSound BioventuresSambrinvestWallonie Entreprendre
DeuterOncology is a clinical-stage biotech developing DO-2, a deuterated, brain-penetrant MET kinase and RAS pathway inhibitor for cancer patients, currently in a phase 1 clinical study.
BiotechHealthtechMedical DevicesLiege, BE
Timothy Perera(PhD Founder & CEO)in
Neuvasq Biotechnologies is a biotech spin-off from the Université libre de Bruxelles developing therapies that target the Gpr124/Reck signaling complex to repair the blood-brain and blood-CNS barriers in neurological and cerebrovascular disorders.
BiotechDeep TechHealthtechMedical Devices
Benoit Vanhollebeke(Scientific Founder)inDenis Bedoret(Executive Director)in
Co-investorsSambrinvestWallonie Entreprendre
Sequana Medical develops the alfapump system and DSR therapy for treating fluid overload in patients with conditions such as liver disease and heart failure.
BiotechHealthtechMedical DevicesGhent, BE
Co-investorsKreos CapitalBlackRockEQT Life SciencesRosetta Capital Ltd.VI PartnersBootstrap Europe+3 more
PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.
AI & Machine LearningBiotechDeep TechTokyo, JP
Co-investorsDBJ CapitalEisai Innovation, Inc.
Acticor Biotech develops Glenzocimab, a therapeutic candidate targeting GPVI for treating acute ischemic stroke and STEMI.
BiotechDigital HealthMedical Devices
Gilles AVENARD(Chief Executive Officer)
Co-investorsAgoranovCapDecisif ManagementKaristaAnaxagoGO Capital
AdipoPharma is a biotech company developing therapies based on the endocrine biology of adipose tissue and targeted rare genetic disorders.
BiotechHealthtechLongevityMedical DevicesStrasbourg, FR
Vincent Marion(Founder)inCatherine Perot(Chief Financial Officer)inMichael J. Fare(Chief Operating Officer)inTarekegn G. Hiwot(Chief Medical Officer)
Co-investorsGood Growth Capital
Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.
BiotechMedical Devices
Co-investorsAdBio partnersAsabys PartnersJeito CapitalNovo HoldingsPMVV-Bio Ventures
Dim3 provides medical device software and hardware for clinical nutrition management, helping doctors, dietitians, and nurses detect malnutrition risks, plan personalized nutrition interventions, and track patient outcomes in real-time across healthcare settings.
Digital HealthHealthtechMedical Devices
EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.
BiotechDigital HealthMedical Devices
Co-investorsFund+
Perseus Proteomics develops and supplies research antibodies targeting nuclear receptors and transcription factors, along with ELISA kits and diagnostic assays, serving life sciences researchers and pharmaceutical development.
BiotechDeep TechHealthtechMedical Devices
Co-investorsDBJ CapitalKyoto University Innovation CapitalNippon Venture CapitalSMBC Venture Capital
Santero is a Belgium-based biotech company developing antibacterial drugs, including an RSH inhibitor programme targeting Pseudomonas aeruginosa and multidrug-resistant pathogens.
AI & Machine LearningBiotechDeep TechHealthtechBrussels, BE
Abel Garcia-Pino(Co-founder & Scientific Advisor)inCédric Govaerts(Co-founder & Scientific Advisor)inMark Beards(Chief Executive Officer)inEmilie Racine(COO & Head of Chemistry)inCuong Vuong(Chief Scientific Officer)inValérie Gallien(Chief of Staff)in
Co-investorsSambrinvest
Synergia Medical develops optoelectronic implantable medical devices, including its NAO.VNS vagus nerve stimulation system, which is undergoing First-In-Human clinical evaluation through the AURORA study.
Deep TechHealthtechMedical DevicesBrussels, BE
Charles Nolet(CEO)inVincent De Rudder(VP QARA)Gijs Klarenbeek(VP of Clinical)Dan Scherrer(COO)inDimitri Crelot(CFO)in
Tensegrity Pharma develops early-stage clinical development programs and drug discovery services for the pharmaceutical industry.
BiotechDeep TechHealthtechMedical Devices
Takahito Nakahara(Founder, President & CEO)
EditForce develops proprietary PPR gene-editing technology that can modify both DNA and RNA, with applications in medicine, agriculture, and chemical industries.
AI & Machine LearningBiotechFukuoka, JP
小野 高(代表取締役社長 CEO)
Co-investorsGlobal BrainKDDI Open Innovation FundUTEC
J-Pharma is a drug development company focused on SLC transporter-targeted therapies, with its lead LAT1 inhibitor nanvuranlat (JPH203) in a global Phase 3 trial for biliary tract cancer and other candidates addressing cancer, autoimmune, and rare diseases.
BiotechDigital HealthHealthtechMedical DevicesTokyo, JP
𠮷武 益広(代表取締役社長 (Representative Director & President))藤本 裕(取締役CFO)山本 寛(取締役CBO)
Co-investorsF-Prime CapitalKSP, Inc.Oita Venture CapitalOSAKA University Venture CapitalSeibu Shinkin CapitalUntroD Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CellaïonEditForce
Frequently asked questions
- How many investments has Newton Biocapital made?
- Newton Biocapital has 18 tracked investments.
- What stage does Newton Biocapital invest at?
- Newton Biocapital invests at the Seed, Series A stages.
- What sectors does Newton Biocapital focus on?
- Newton Biocapital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Newton Biocapital located?
- Newton Biocapital is headquartered in Brussels, BE.
- Does Newton Biocapital lead rounds?
- Yes, Newton Biocapital leads investment rounds.
- Who does Newton Biocapital co-invest with?
- Newton Biocapital most often shares deals with DBJ Capital, Fund+, F-Prime Capital, among 26 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.